To describe the efficacy of infigratinib, a potent, selective fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitor, across lines of therapy (LOT) in patients with metastatic urothelial cancer (mUC).
Eligible patients had mUC and prior platinum-based chemotherapy, unless contraindicated, and activating FGFR3 mutation/fusion. Patients received infigratinib 125 mg orally daily (3 weeks on/1 week off) in a single-arm, open-label study. Primary endpoint: investigator-assessed confirmed objective response rate (ORR). Disease control rate (DCR), progression-free survival (PFS), best overall response (BOR) that included unconfirmed responses, and overall survival (OS) were also assessed. Subgroup analysis of efficacy and safety outcomes by LOT was performed.
Sixty-seven patients were enrolled; 13 (19.4%) received infigratinib as early-line therapy for mUC due to ineligibility to receive platinum-based chemotherapy. Overall, ORR was 25.4% (95% CI 15.5-37.5) and DCR was 64.2% (95% CI 51.5-75.5). ORR was 30.8% (95% CI 9.1-61.4) with early-line infigratinib and 24.1% (95% CI 13.5-37.6) for ≥2 LOT. DCR was 46.2% (95% CI 19.2-74.9) for early-line and 68.5% (95% CI 54.4-80.5) for ≥2 LOT. PFS and OS appeared similar in both groups. Thirteen of 59 patients with a bladder primary tumor received early-line treatment with an ORR of 30.5% (95% CI 9.1-61.4), and 46 received ≥2 LOT with an ORR of 20.3% (95% CI 9.4-33.9); BOR was 38.5% (95% CI: 13.9-68.4%) and 42.6% (95% CI: 29.2-56.8%) in the early-line and salvage settings, respectively. Eight patients with upper tract urothelial carcinoma received salvage therapy (ORR, 50.0%; DCR, 100.0%). No significant differences in toxicities between LOT were observed.
Infigratinib has notable activity in patients with mUC regardless of LOT. The findings support the evaluation of infigratinib across different settings in mUC.
Clinical genitourinary cancer. 2021 Oct 13 [Epub ahead of print]
Yung Lyou, Jonathan E Rosenberg, Jean Hoffman-Censits, David I Quinn, Daniel Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard Burris, Jessica Rearden, Ai Li, Cindy Xu, Corina Andresen, Susan Moran, Siamak Daneshmand, Dean Bajorin, Sumanta K Pal, Petros Grivas
City of Hope Comprehensive Cancer Center, Duarte, CA., Memorial Sloan Kettering Cancer Center, New York, NY., Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD., USC Norris Comprehensive Cancer Center, Los Angeles, CA., Yale Cancer Center, Smilow Cancer Hospital, New Haven, CT., Mount Sinai School of Medicine, New York, NY., Karmanos Cancer Center, Wayne State University, Detroit, Ml., lstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy., Huntsman Cancer Institute - University of Utah Health Care, Salt Lake City, UT., Sarah Cannon Research Institute, Nashville, TN., QED Therapeutics, Inc., San Francisco, CA., USC/Norris Comprehensive Cancer Center Institute of Urology, Los Angeles, CA., University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: .